CERT Certara

Certara Appoints New Chief Human Resources Officer & General Counsel

Certara Appoints New Chief Human Resources Officer & General Counsel

RADNOR, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has appointed as Chief Human Resources Officer and as General Counsel.

"Rona and Daniel are leaders in their fields. They have proven track records of growing teams and building high-performing businesses," said , Certara. "I’m confident they will further Certara’s mission of accelerating medicines to patients through the delivery of solutions that improve the entire drug research and development process.”

Ms. Anhalt will drive Certara’s human capital management strategy. She will lead the company’s global Human Resources function supporting Certara’s 1,400 team members including more than 400 scientists across the globe. She has over 20 years of experience supporting strategic growth and building high-performing teams in life sciences. In her prior role at EQRx, Ms. Anhalt led HR from start-up through acquisition and championed a mission-oriented culture.

"I’ve spent my career in life sciences and am excited to lead Certara’s people strategy and build on an organization that expedites bringing more safe and effective drugs to market,” said Rona Anhalt.

Daniel Corcoran will oversee Certara’s legal affairs. He has over 20 years of experience in publicly traded and privately held global technology companies. Previously, he was the Senior Vice President of Legal and General Counsel at Nexthink where he led legal and compliance teams and helped the company prepare for its IPO.

“Certara is a leader in bringing powerful drug discovery and development solutions to researchers worldwide and preparing for its next stage of technology-driven growth,” said Daniel Corcoran. "I’m excited to join a team that positively impacts people around the world waiting for treatments and cures.”

About Certara

Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Learn more at certara.com.

Certara Contact:

Sheila Rocchio

Media Contact:

Alyssa Horowitz



EN
21/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Certara

 PRESS RELEASE

Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advan...

Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform Strengthening technology innovation and leadership of the Certara AI/ML-enabled biosimulation platform used to speed time to market in drug discovery and development RADNOR, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D., as Chief Technology Officer. In this role, Bouton will lead technology strategy and development of a next-gene...

 PRESS RELEASE

Certara to Report Second Quarter 2025 Financial Results on August 6th,...

Certara to Report Second Quarter 2025 Financial Results on August 6th, 2025 RADNOR, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2025 after the market close on Wednesday, August 6th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to It is recommended to register at least one day in advance. A live and archived webc...

 PRESS RELEASE

Certara Announces Expansion of Clinical Technology Collaboration with ...

Certara Announces Expansion of Clinical Technology Collaboration with Merck Expands use of the Certara Pinnacle 21® (P21) enterprise software platform to optimize clinical data flows for speed and quality RADNOR, Pa., July 08, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced a new collaboration with Merck, known as MSD outside of the United States and Canada, that expands Merck’s use of the Certara Pinnacle 21 software platform to include a metadata repository and data standards workflow management. This agreement...

 PRESS RELEASE

Certara Reports First Quarter 2025 Financial Results

Certara Reports First Quarter 2025 Financial Results Reiterates Full Year 2025 Financial Guidance RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the first quarter of fiscal year 2025. First Quarter Highlights: Revenue was $106.0 million, compared to $96.7 million in the first quarter of 2024, representing growth of 10%. Software revenue was $46.4 million, compared to $39.3 million in the first quarter of 2024, representing growth of 18%.Services revenue w...

 PRESS RELEASE

Certara to Participate in Upcoming Investor Conferences

Certara to Participate in Upcoming Investor Conferences RADNOR, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: BofA Securities 2025 Healthcare ConferenceDate and Time: Tuesday, May 13 at 3:40 p.m. PT William Blair 45th Annual Growth Stock ConferenceDate and Time: Wednesday, June 4 at 12:40 p.m. CT Live webcasts for each of the conferences will be available on Certara’s investor relations website at and will be availa...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch